COMMUNIQUÉS West-GlobeNewswire
-
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
07/07/2026 -
Transactions in connection with share buy-back program
07/07/2026 -
Levicept Appoints Darlene Deptula-Hicks as CFO
07/07/2026 -
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
07/07/2026 -
Rapid Nutrition Showcases HealthTech Strategy on Bloomberg Television
07/07/2026 -
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
07/07/2026 -
Clareo Plastic Surgery Named Best Plastic Surgery Practice in Boston
06/07/2026 -
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07/2026 -
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
06/07/2026 -
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026 -
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
06/07/2026 -
Abivax annonce la réalisation de son offre au public de 920 millions de dollars
06/07/2026 -
Abivax Announces Closing of $920 Million Public Offering
06/07/2026 -
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
06/07/2026 -
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
06/07/2026 -
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/07/2026 -
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
06/07/2026 -
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/07/2026 -
Longeveron® Appoints Marie Washburn as Chief Financial Officer
06/07/2026
Pages